Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study

Niall C. Tebbutt, Kate Wilson, Val J. Gebski, Michelle M. Cummins, Diana Zannino, Guy A. Van Hazel, Bridget Robinson, Adam Broad, Vinod Ganju, Stephen P. Ackland, Garry Forgeson, David Cunningham, Mark P. Saunders, Martin R. Stockler, Yujo Chua, John R. Zalcberg, R. John Simes, Timothy J. Price

Research output: Contribution to journal › Article › peer-review

376 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science